HOME > TOP STORIES
TOP STORIES
-
BUSINESS As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
February 15, 2023
-
BUSINESS BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
February 14, 2023
-
BUSINESS Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
February 13, 2023
-
REGULATORY Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
-
REGULATORY Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
-
BUSINESS Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
February 10, 2023
-
REGULATORY Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
-
BUSINESS CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
-
BUSINESS Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
-
REGULATORY Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
February 6, 2023
-
BUSINESS Astellas EVP Okamura to Become CEO in April
February 6, 2023
-
BUSINESS Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
February 6, 2023
-
BUSINESS Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
-
REGULATORY Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
-
BUSINESS Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
February 1, 2023
-
BUSINESS Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
-
BUSINESS Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
-
REGULATORY Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
-
REGULATORY It’s Official: Japan to Downgrade COVID-19 Severity Status on May 8
January 30, 2023
-
REGULATORY Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…